PropertyValue
?:abstract
  • Familial Mediterranean Fever (FMF) and COVID-19 show a remarkable overlap of clinical symptoms and similar laboratory findings. Both are characterized by fever, abdominal/chest pain, elevation of C-reactive protein, and leukocytosis. In addition, colchicine and IL-1 inhibitors treatments that are effective in controlling inflammation in FMF patients have recently been proposed for off-label use in COVID-19 patients. Thus, FMF may resemble a milder recapitulation of the cytokine storm that is a hallmark of COVID-19 patients progressing to severe disease. We analyzed the sequence of the MEFV-encoded Pyrin protein – whose mutations cause FMF- in mammals, bats and pangolin. Intriguingly, although Pyrin is extremely conserved in species that are considered either a reservoir or intermediate hosts for SARS-CoV-2, some of the most common FMF-causing variants in humans are present as wildtype residues in these species. We propose that in humans, Pyrin may have evolved to fight highly pathogenic infections.
is ?:annotates of
?:creator
?:doi
  • 10.3389/fimmu.2020.574593
?:doi
?:journal
  • Front_Immunol
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/e254c05d34c8d788a4e438d4aa2bf88b3e413941.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7530822.xml.json
?:pmcid
?:pmid
?:pmid
  • 33072117.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Familial Mediterranean Fever and COVID-19: Friends or Foes?
?:type
?:year
  • 2020-09-18

Metadata

Anon_0  
expand all